Group of Urological Molecular Biology Publications

Guldvik IJ, Ramberg H, Kristensen G, Røder A, Mills IG, Lilleby W, Taskén KA (2024)
Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy
World J Urol, 42 (1), 95
DOI 10.1007/s00345-024-04787-8, PubMed 38386171

Guldvik IJ, Braadland PR, Sivanesan S, Ramberg H, Kristensen G, Tennstedt P, Røder A, Schlomm T, Berge V, Eri LM, Lilleby W, Mills IG, Taskén KA (2022)
Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
Eur Urol Open Sci, 45, 68-75
DOI 10.1016/j.euros.2022.09.002, PubMed 36353660

Nunes-Xavier CE, Emaldi M, Guldvik IJ, Ramberg H, Taskén KA, Mælandsmo GM, Fodstad Ø, Llarena R, Pulido R, López JI (2022)
Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer
Pathol Res Pract, 241, 154243
DOI 10.1016/j.prp.2022.154243, PubMed 36481650

Ouellet V, Erickson A, GAP1 UTMAs Contributing Investigators, Wiley K, Morrissey C, Berge V, Moreno CS, Tasken KA, Trudel D, True LD, Lewis MS, Svindland A, Ertunc O, Vidal ID, Osunkoya AO, Jones T, Bova GS, Lamminen T, Achtman AH, Buzza M, Kouspou MM, Bigler SA, Zhou X, Freedland SJ, Mes-Masson AM et al. (2022)
The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource
Cancer Epidemiol Biomarkers Prev, 31 (4), 715-727
DOI 10.1158/1055-9965.EPI-21-0600, PubMed 35131885

Sivanesan S, Taskén KA, Grytli HH (2022)
Association of β-Blocker Use at Time of Radical Prostatectomy With Rate of Treatment for Prostate Cancer Recurrence
JAMA Netw Open, 5 (1), e2145230
DOI 10.1001/jamanetworkopen.2021.45230, PubMed 35080602

Guerriero I, Ramberg H, Sagini K, Ramirez-Garrastacho M, Taskén KA, Llorente A (2021)
Implication of β2-adrenergic receptor and miR-196a correlation in neurite outgrowth of LNCaP prostate cancer cells
PLoS One, 16 (6), e0253828
DOI 10.1371/journal.pone.0253828, PubMed 34191854

Guldvik IJ, Ekseth L, Kishan AU, Stensvold A, Inderberg EM, Lilleby W (2021)
Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer
J Pers Med, 11 (7)
DOI 10.3390/jpm11070605, PubMed 34206815

Moghaddam S, Jalali A, O'Neill A, Murphy L, Gorman L, Reilly AM, Heffernan Á, Lynch T, Power R, O'Malley KJ, Taskèn KA, Berge V, Solhaug VA, Klocker H, Murphy TB, Watson RW (2021)
Integrating Serum Biomarkers into Prediction Models for Biochemical Recurrence Following Radical Prostatectomy
Cancers (Basel), 13 (16)
DOI 10.3390/cancers13164162, PubMed 34439316

Ramberg H, Richardsen E, de Souza GA, Rakaee M, Stensland ME, Braadland PR, Nygård S, Ögren O, Guldvik IJ, Berge V, Svindland A, Taskén KA, Andersen S (2021)
Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer
Carcinogenesis, 42 (5), 685-693
DOI 10.1093/carcin/bgab015, PubMed 33609362

Ramirez-Garrastacho M, Bajo-Santos C, Line A, Martens-Uzunova ES, de la Fuente JM, Moros M, Soekmadji C, Tasken KA, Llorente A (2021)
Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research
Br J Cancer, 126 (3), 331-350
DOI 10.1038/s41416-021-01610-8, PubMed 34811504

van der Zanden TM, Mooij MG, Vet NJ, Neubert A, Rascher W, Lagler FB, Male C, Grytli H, Halvorsen T, de Hoog M, de Wildt SN (2021)
Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo Framework
Clin Pharmacol Ther, 110 (4), 952-965
DOI 10.1002/cpt.2336, PubMed 34145575

Guldvik IJ, Zuber V, Braadland PR, Grytli HH, Ramberg H, Lilleby W, Thiede B, Zucknick M, Saatcioglu F, Gislefoss R, Kvåle R, George A, Grönberg H, Wiklund F, Neal DE, Gnanapragasam VJ, Taskén KA, Mills IG (2020)
Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
Eur Urol Open Sci, 21, 51-60
DOI 10.1016/j.euros.2020.08.007, PubMed 34337468

Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, Bjartell A, Taskén KA (2019)
The β₂-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
Mol Cancer Res, 17 (11), 2154-2168
DOI 10.1158/1541-7786.MCR-18-0605, PubMed 31395667

Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X (2019)
Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
Int J Cancer, 146 (1), 223-235
DOI 10.1002/ijc.32638, PubMed 31444972

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Richardsen E, Andersen S, Al-Saad S, Rakaee M, Nordby Y, Pedersen MI, Ness N, Ingebriktsen LM, Fassina A, Taskén KA, Mills IG, Donnem T, Bremnes RM, Busund LT (2019)
Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer
Sci Rep, 9 (1), 10662
DOI 10.1038/s41598-019-47234-0, PubMed 31337863

Berg J, Halvorsen AR, Bengtson MB, Taskén KA, Mælandsmo GM, Yndestad A, Halvorsen B, Brustugun OT, Aukrust P, Ueland T, Helland Å (2018)
Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
BMC Cancer, 18 (1), 739
DOI 10.1186/s12885-018-4659-0, PubMed 30005623

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2018)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 118 (6), e11
DOI 10.1038/bjc.2017.470, PubMed 29462127

Prencipe M, Fabre A, Murphy TB, Vargyas E, O'Neill A, Bjartell A, Tasken KA, Grytli HH, Svindland A, Berge V, Eri LM, Gallagher W, Watson RW (2018)
Role of serum response factor expression in prostate cancer biochemical recurrence
Prostate, 78 (10), 724-730
DOI 10.1002/pros.23516, PubMed 29608018

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2017)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 117 (11), 1656-1664
DOI 10.1038/bjc.2017.346, PubMed 28972967

Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, Erho N, Bloch K, Davicioni E, Derua R, Waelkens E, Mohler JL, Clarke N, Swinnen JV, Keun HC, Rekvig OP, Mills IG (2017)
Lipid degradation promotes prostate cancer cell survival
Oncotarget, 8 (24), 38264-38275
DOI 10.18632/oncotarget.16123, PubMed 28415728

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA (2016)
Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
Oncotarget, 7 (2), 1878-94
DOI 10.18632/oncotarget.6479, PubMed 26646591

Moen LV, Ramberg H, Zhao S, Grytli HH, Sveen A, Berge V, Skotheim RI, Taskén KA, Skålhegg BS (2016)
Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness
Urol Oncol, 35 (3), 111.e1-111.e8
DOI 10.1016/j.urolonc.2016.10.002, PubMed 27838142

Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R (2016)
Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA
Clin Nutr, 36 (3), 672-679
DOI 10.1016/j.clnu.2016.06.014, PubMed 27406859

Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA (2016)
PBX3 is a putative biomarker of aggressive prostate cancer
Int J Cancer, 139 (8), 1810-20
DOI 10.1002/ijc.30220, PubMed 27273830

Bollineni RC, Guldvik IJ, Grönberg H, Wiklund F, Mills IG, Thiede B (2015)
A differential protein solubility approach for the depletion of highly abundant proteins in plasma using ammonium sulfate
Analyst, 140 (24), 8109-17
DOI 10.1039/c5an01560j, PubMed 26541119

Braadland PR, Ramberg H, Grytli HH, Taskén KA (2015)
β-Adrenergic Receptor Signaling in Prostate Cancer
Front Oncol, 4, 375
DOI 10.3389/fonc.2014.00375, PubMed 25629002

Itkonen HM, Engedal N, Babaie E, Luhr M, Guldvik IJ, Minner S, Hohloch J, Tsourlakis MC, Schlomm T, Mills IG (2014)
UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation
Oncogene, 34 (28), 3744-50
DOI 10.1038/onc.2014.307, PubMed 25241896

Eide T, Ramberg H, Glackin C, Tindall D, Taskén KA (2013)
TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells
Cancer Cell Int, 13 (1), 4
DOI 10.1186/1475-2867-13-4, PubMed 23368843

Engedal N, Torgersen ML, Guldvik IJ, Barfeld SJ, Bakula D, Sætre F, Hagen LK, Patterson JB, Proikas-Cezanne T, Seglen PO, Simonsen A, Mills IG (2013)
Modulation of intracellular calcium homeostasis blocks autophagosome formation
Autophagy, 9 (10), 1475-90
DOI 10.4161/auto.25900, PubMed 23970164

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
Int J Cancer, 133 (6), 1497-506
DOI 10.1002/ijc.28158, PubMed 23494569

Grytli HH, Fagerland MW, Fosså SD, Taskén KA (2013)
Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease
Eur Urol, 65 (3), 635-41
DOI 10.1016/j.eururo.2013.01.007, PubMed 23351721

Grytli HH, Fagerland MW, Fosså SD, Taskén KA (2013)
Reply to Chris R. Cardwell, Samy Suissa and Liam J. Murray's letter to the editor re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, Kristin Austlid Taskén. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007
Eur Urol, 64 (1), e11-2
DOI 10.1016/j.eururo.2013.03.045, PubMed 23602404

Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, Svindland A, Schlomm T, Mills IG (2013)
O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells
Cancer Res, 73 (16), 5277-87
DOI 10.1158/0008-5472.CAN-13-0549, PubMed 23720054

Grytli HH, Fagerland MW, Fosså SD, Taskén KA, Håheim LL (2012)
Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy
Prostate, 73 (3), 250-60
DOI 10.1002/pros.22564, PubMed 22821802

Lazarevic B, Hammarström C, Yang J, Ramberg H, Diep LM, Karlsen SJ, Kucuk O, Saatcioglu F, Taskèn KA, Svindland A (2012)
The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy
Br J Nutr, 108 (12), 2138-47
DOI 10.1017/S0007114512000384, PubMed 22397815

Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg RE, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Taskèn KA, Karlsen SJ (2011)
Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial
Nutr Cancer, 63 (6), 889-98
DOI 10.1080/01635581.2011.582221, PubMed 21714686

Ramberg H, Alshbib A, Berge V, Svindland A, Taskén KA (2011)
Regulation of PBX3 expression by androgen and Let-7d in prostate cancer
Mol Cancer, 10, 50
DOI 10.1186/1476-4598-10-50, PubMed 21548940

Risberg K, Guldvik IJ, Palchaudhuri R, Xi Y, Ju J, Fodstad O, Hergenrother PJ, Andersson Y (2011)
Triphenylmethyl derivatives enhances the anticancer effect of immunotoxins
J Immunother, 34 (5), 438-47
DOI 10.1097/CJI.0b013e31821e00ae, PubMed 21577141

Røtterud R, Malmström PU, Wahlqvist R, Taskén KA (2010)
The star chart to Ta bladder cancer: an unsophisticated analysis of two-dimensional gel electrophoresis proteome maps
Scand J Urol Nephrol, 44 (2), 76-83
DOI 10.3109/00365590903510729, PubMed 20059407

Perander M, Aberg E, Johansen B, Dreyer B, Guldvik IJ, Outzen H, Keyse SM, Seternes OM (2008)
The Ser(186) phospho-acceptor site within ERK4 is essential for its ability to interact with and activate PRAK/MK5
Biochem J, 411 (3), 613-22
DOI 10.1042/BJ20071369, PubMed 18248330

Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA (2008)
Hormonal regulation of beta2-adrenergic receptor level in prostate cancer
Prostate, 68 (10), 1133-42
DOI 10.1002/pros.20778, PubMed 18454446

Kvissel AK, Ramberg H, Eide T, Svindland A, Skålhegg BS, Taskén KA (2006)
Androgen dependent regulation of protein kinase A subunits in prostate cancer cells
Cell Signal, 19 (2), 401-9
DOI 10.1016/j.cellsig.2006.07.011, PubMed 16949795

Dizeyi N, Bjartell A, Hedlund P, Taskén KA, Gadaleanu V, Abrahamsson PA (2005)
Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines
Eur Urol, 47 (6), 895-900
DOI 10.1016/j.eururo.2005.02.006, PubMed 15925089

Taskén KA, Angelsen A, Svindland A, Eide T, Berge V, Wahlquist R, Karlsen S (2005)
[Markers for diagnosis, prediction and prognosis of prostate cancer]
Tidsskr Nor Laegeforen, 125 (23), 3279-82
PubMed 16327854

Eide T, Taskén KA, Carlson C, Williams G, Jahnsen T, Taskén K, Collas P (2003)
Protein kinase A-anchoring protein AKAP95 interacts with MCM2, a regulator of DNA replication
J Biol Chem, 278 (29), 26750-6
DOI 10.1074/jbc.M300765200, PubMed 12740381

Dahle MK, Grønning LM, Cederberg A, Blomhoff HK, Miura N, Enerbäck S, Taskén KA, Taskén K (2002)
Mechanisms of FOXC2- and FOXD1-mediated regulation of the RI alpha subunit of cAMP-dependent protein kinase include release of transcriptional repression and activation by protein kinase B alpha and cAMP
J Biol Chem, 277 (25), 22902-8
DOI 10.1074/jbc.M200131200, PubMed 11943768

Dahle MK, Taskén K, Taskén KA (2002)
USF2 inhibits C/EBP-mediated transcriptional regulation of the RIIbeta subunit of cAMP-dependent protein kinase
BMC Mol Biol, 3, 10
DOI 10.1186/1471-2199-3-10, PubMed 12086590

Eide T, Carlson C, Taskén KA, Hirano T, Taskén K, Collas P (2002)
Distinct but overlapping domains of AKAP95 are implicated in chromosome condensation and condensin targeting
EMBO Rep, 3 (5), 426-32
DOI 10.1093/embo-reports/kvf089, PubMed 11964380

Dahle MK, Knutsen HK, Taskén KA, Pilz R, Taskén K (2001)
Cyclic AMP regulates expression of the RI alpha subunit of cAMP-dependent protein kinase through an alternatively spliced 5' UTR
Eur J Biochem, 268 (22), 5920-9
DOI 10.1046/j.0014-2956.2001.02542.x, PubMed 11722580

Dahle MK, Reinton N, Orstavik S, Taskén KA, Taskén K (2001)
Novel alternatively spliced mRNA (1c) of the protein kinase A RIα subunit is implicated in haploid germ cell specific expression
Mol Reprod Dev, 59 (1), 11-6
DOI 10.1002/mrd.1001, PubMed 11335941

Taskén KA, Collas P, Kemmner WA, Witczak O, Conti M, Taskén K (2001)
Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area
J Biol Chem, 276 (25), 21999-2002
DOI 10.1074/jbc.C000911200, PubMed 11285255

Grønning LM, Wang JE, Ree AH, Haugen TB, Taskén K, Taskén KA (2000)
Regulation of tissue inhibitor of metalloproteinases-1 in rat Sertoli cells: induction by germ cell residual bodies, interleukin-1alpha, and second messengers
Biol Reprod, 62 (4), 1040-6
DOI 10.1095/biolreprod62.4.1040, PubMed 10727275

Olson BJ, Skavdahl M, Ramberg H, Osterman JC, Markwell J (2000)
Formate dehydrogenase in Arabidopsis thaliana: characterization and possible targeting to the chloroplast
Plant Sci, 159 (2), 205-212
DOI 10.1016/s0168-9452(00)00337-x, PubMed 11074273

Gronning LM, Knutsen HK, Eskild W, Hansson V, Taskén K, Taskén KA (1999)
Method of transfection affects the cAMP-mediated induction of the RIIbeta subunit of protein kinase A in Sertoli cells: inhibition of response by increase in intracellullar calcium
Eur J Endocrinol, 141 (1), 75-82
DOI 10.1530/eje.0.1410075, PubMed 10407227

Grønning LM, Dahle MK, Taskén KA, Enerbäck S, Hedin L, Taskén K, Knutsen HK (1999)
Isoform-specific regulation of the CCAAT/enhancer-binding protein family of transcription factors by 3',5'-cyclic adenosine monophosphate in Sertoli cells
Endocrinology, 140 (2), 835-43
DOI 10.1210/endo.140.2.6526, PubMed 9927313

Ree AH, Hansson V, Walaas SI, Eskild W, Taskén KA (1999)
Calcium/phospholipid-dependent protein kinases in rat Sertoli cells: regulation of androgen receptor messenger ribonucleic acid
Biol Reprod, 60 (5), 1257-62
DOI 10.1095/biolreprod60.5.1257, PubMed 10208993

Knutsen HK, Taskén K, Eskild W, Richards JS, Kurten RC, Torjesen PA, Jahnsen T, Hansson V, Guérin S, Taskén KA (1997)
Characterization of the 5'-flanking region of the gene for the cAMP-inducible protein kinase A subunit, RIIbeta, in Sertoli cells
Mol Cell Endocrinol, 129 (1), 101-14
DOI 10.1016/s0303-7207(97)04045-8, PubMed 9175634

Taskén K, Skålhegg BS, Taskén KA, Solberg R, Knutsen HK, Levy FO, Sandberg M, Orstavik S, Larsen T, Johansen AK, Vang T, Schrader HP, Reinton NT, Torgersen KM, Hansson V, Jahnsen T (1997)
Structure, function, and regulation of human cAMP-dependent protein kinases
Adv Second Messenger Phosphoprotein Res, 31, 191-204
DOI 10.1016/s1040-7952(97)80019-5, PubMed 9344252

Knutsen HK, Reinton N, Taskén KA, Hansson V, Eskild W (1996)
Regulation of protein kinase A subunits by cyclic adenosine 3',5'-monophosphate in a mouse Sertoli cell line (MSC-1): induction of RII beta messenger ribonucleic acid is independent of continuous protein synthesis
Biol Reprod, 55 (1), 5-10
DOI 10.1095/biolreprod55.1.5, PubMed 8793051

Taskén KA, Jacobsen FW, Eikvar L, Hansson V, Haugen TB (1995)
The alpha-subunit mRNAs for Gs and Go2 are differentially regulated by protein kinase A and protein kinase C in rat Sertoli cells
Biochim Biophys Acta, 1260 (3), 269-75
DOI 10.1016/0167-4781(94)00203-f, PubMed 7873600

Eikvar L, Taskén KA, Eskild W, Hansson V (1993)
Protein kinase C activation and positive and negative agonist regulation of 3',5'-cyclic adenosine monophosphate levels in cultured rat Sertoli cells
Acta Endocrinol (Copenh), 128 (6), 568-72
DOI 10.1530/acta.0.1280568, PubMed 7687809

Taskén K, Andersson KB, Skålhegg BS, Taskén KA, Hansson V, Jahnsen T, Blomhoff HK (1993)
Reciprocal regulation of mRNA and protein for subunits of cAMP-dependent protein kinase (RI alpha and C alpha) by cAMP in a neoplastic B cell line (Reh)
J Biol Chem, 268 (31), 23483-9
PubMed 8226875

Knutsen HK, Taskén KA, Eskild W, Hansson V (1992)
Inhibitors of RNA and protein synthesis stabilize messenger RNA for the RII beta subunit of protein kinase A in different cellular compartments
Biochem Biophys Res Commun, 183 (2), 632-9
DOI 10.1016/0006-291x(92)90529-t, PubMed 1550570

Knutsen HK, Taskén KA, Eskild W, Jahnsen T, Hansson V (1992)
Half-lives of different sized mRNAs for the PKA subunit RI alpha are regulated differently in response to inhibition of transcription and translation
Biochem Biophys Res Commun, 184 (1), 454-60
DOI 10.1016/0006-291x(92)91215-c, PubMed 1314594

Taskén KA, Knutsen HK, Eikvar L, Taskén K, Eskild W, Jahnsen T, Hansson V (1992)
Protein kinase C activation by 12-O-tetradecanoylphorbol 13-acetate modulates messenger ribonucleic acid levels for two of the regulatory subunits of 3',5'-cyclic adenosine monophosphate-dependent protein kinases (RII beta and RI alpha) via multiple and distinct mechanisms
Endocrinology, 130 (3), 1271-80
DOI 10.1210/endo.130.3.1311233, PubMed 1311233

Knutsen HK, Taskén KA, Eskild W, Jahnsen T, Hansson V (1991)
Adenosine 3',5'-monophosphate-dependent stabilization of messenger ribonucleic acids (mRNAs) for protein kinase-A (PKA) subunits in rat Sertoli cells: rapid degradation of mRNAs for PKA subunits is dependent on ongoing RNA and protein synthesis
Endocrinology, 129 (5), 2496-502
DOI 10.1210/endo-129-5-2496, PubMed 1657577

Taskén KA, Knutsen HK, Attramadal H, Taskén K, Jahnsen T, Hansson V, Eskild W (1991)
Different mechanisms are involved in cAMP-mediated induction of mRNAs for subunits of cAMP-dependent protein kinases
Mol Endocrinol, 5 (1), 21-8
DOI 10.1210/mend-5-1-21, PubMed 1850108